These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

376 related items for PubMed ID: 24444466

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.
    Cao XX, Li J, Cai H, Zhang W, Duan MH, Zhou DB.
    Ann Hematol; 2017 Nov; 96(11):1867-1871. PubMed ID: 28803429
    [Abstract] [Full Text] [Related]

  • 4. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
    Choi JW, Kim Y, Lee JH, Kim YS.
    Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
    [Abstract] [Full Text] [Related]

  • 5. MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.
    Aggarwal V, Das A, Bal A, Srinivasan R, Das R, Prakash G, Malhotra P, Varma S.
    Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):311-318. PubMed ID: 29734251
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Zheng M, Perry AM, Bierman P, Loberiza F, Nasr MR, Szwajcer D, Del Bigio MR, Smith LM, Zhang W, Greiner TC.
    Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
    [Abstract] [Full Text] [Related]

  • 8. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
    Dubois S, Viailly PJ, Bohers E, Bertrand P, Ruminy P, Marchand V, Maingonnat C, Mareschal S, Picquenot JM, Penther D, Jais JP, Tesson B, Peyrouze P, Figeac M, Desmots F, Fest T, Haioun C, Lamy T, Copie-Bergman C, Fabiani B, Delarue R, Peyrade F, André M, Ketterer N, Leroy K, Salles G, Molina TJ, Tilly H, Jardin F.
    Clin Cancer Res; 2017 May 01; 23(9):2232-2244. PubMed ID: 27923841
    [Abstract] [Full Text] [Related]

  • 9. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
    Yamada S, Ishida Y, Matsuno A, Yamazaki K.
    Leuk Lymphoma; 2015 Jul 01; 56(7):2141-5. PubMed ID: 25347427
    [Abstract] [Full Text] [Related]

  • 10. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.
    Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, Tanaka K, Fukushima S, Takami H, Arita H, Kubo A, Shuto T, Ohno M, Miyakita Y, Kocialkowski S, Sasayama T, Hashimoto N, Maehara T, Shibui S, Ushijima T, Kawahara N, Narita Y, Ichimura K.
    Neuropathol Appl Neurobiol; 2016 Apr 01; 42(3):279-90. PubMed ID: 26111727
    [Abstract] [Full Text] [Related]

  • 11. Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
    Chen Z, Zou Y, Liu W, Guan P, Tao Q, Xiang C, Zhang W, Ye Y, Yan J, Zhao S.
    Am J Surg Pathol; 2020 Apr 01; 44(4):444-455. PubMed ID: 31609782
    [Abstract] [Full Text] [Related]

  • 12. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.
    Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, Martinez F, Cappellen D, Merlio JP, Grange F.
    JAMA Dermatol; 2014 Nov 01; 150(11):1173-9. PubMed ID: 25055137
    [Abstract] [Full Text] [Related]

  • 13. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
    Bohers E, Mareschal S, Bouzelfen A, Marchand V, Ruminy P, Maingonnat C, Ménard AL, Etancelin P, Bertrand P, Dubois S, Alcantara M, Bastard C, Tilly H, Jardin F.
    Genes Chromosomes Cancer; 2014 Feb 01; 53(2):144-53. PubMed ID: 24327543
    [Abstract] [Full Text] [Related]

  • 14. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR.
    Zhong Y, Tan GW, Bult J, Veltmaat N, Plattel W, Kluiver J, Enting R, Diepstra A, van den Berg A, Nijland M.
    BMC Cancer; 2024 Apr 02; 24(1):407. PubMed ID: 38566053
    [Abstract] [Full Text] [Related]

  • 15. Nomogram for predicting survival of patients with diffuse large B-cell lymphoma.
    Fujii K, Inagaki A, Masaki A, Sugiura M, Suzuki T, Ishida T, Kusumoto S, Iida S, Inagaki H.
    Ann Hematol; 2024 Jun 02; 103(6):2041-2050. PubMed ID: 38411628
    [Abstract] [Full Text] [Related]

  • 16. High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.
    Oishi N, Kondo T, Nakazawa T, Mochizuki K, Tanioka F, Oyama T, Yamamoto T, Iizuka J, Tanabe K, Shibata N, Kirito K, Katoh R.
    Pathol Int; 2015 Oct 02; 65(10):528-35. PubMed ID: 26388135
    [Abstract] [Full Text] [Related]

  • 17. Oncogenically active MYD88 mutations in human lymphoma.
    Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, Kohlhammer H, Xu W, Yang Y, Zhao H, Shaffer AL, Romesser P, Wright G, Powell J, Rosenwald A, Muller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Staudt LM.
    Nature; 2011 Feb 03; 470(7332):115-9. PubMed ID: 21179087
    [Abstract] [Full Text] [Related]

  • 18. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
    Yamaguchi J, Ohka F, Lushun C, Motomura K, Aoki K, Takeuchi K, Nagata Y, Ito S, Mizutani N, Ohno M, Suzaki N, Takasu S, Seki Y, Kano T, Wakabayashi K, Oyama H, Kurahashi S, Tanahashi K, Hirano M, Shimizu H, Kitano Y, Maeda S, Yamazaki S, Wakabayashi T, Kondo Y, Natsume A, Saito R.
    Cancer Med; 2023 Mar 03; 12(6):7116-7126. PubMed ID: 36478416
    [Abstract] [Full Text] [Related]

  • 19. An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma.
    Flümann R, Hansen J, Meinel J, Pfeiffer P, Goldfarb Wittkopf H, Lütz A, Wirtz J, Möllmann M, Zhou T, Tabatabai A, Lohmann T, Jauch M, Beleggia F, Pelzer B, Ullrich F, Höfmann S, Arora A, Persigehl T, Büttner R, von Tresckow B, Klein S, Jachimowicz RD, Reinhardt HC, Knittel G.
    Blood Adv; 2024 Mar 12; 8(5):1063-1074. PubMed ID: 38060829
    [Abstract] [Full Text] [Related]

  • 20. MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.
    Rovira J, Karube K, Valera A, Colomer D, Enjuanes A, Colomo L, Martínez-Trillos A, Giné E, Dlouhy I, Magnano L, Delgado J, Martínez A, Villamor N, Campo E, López-Guillermo A.
    Clin Cancer Res; 2016 Jun 01; 22(11):2755-64. PubMed ID: 26792260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.